1 available, 1 not yet recruiting, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow AVM Biotechnology Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19 | Phase 1 | Not yet recruiting | AVM Biotechnology Inc | 16 | 2026-12-01 | 2025-10-02 |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies AVM0703 - Lymphoid Malignancies | Phase 1 / Phase 2 | Recruiting | AVM Biotechnology Inc | 144 | 2020-11-06 | 2026-04-15 |
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients AVM0703, Hydrocortisone, Proton pump inhibitor - Glioblastoma, Squamous Cell Carcinoma | Available | AVM Biotechnology Inc | 2025-10-02 |
Brain Neoplasms (1) · Breast Neoplasms (1) · COVID-19 (1) · Carcinoma, Squamous Cell (1) · Glioblastoma (1) · Hodgkin Disease (1) · Influenza, Human (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1)
Hydrocortisone (1) · Proton Pump Inhibitors (1)
United States (1)
Daniel Kerr, MD (1) · Don Stevens, MD (1) · Edward Loniewski, D.O. (1) · Elizabeth Budde, MD (1) · Gary Schiller, MD (1) · Lasika Seneviratne, MD (1) · Nashat Gabrail, MD (1) · Pamela Miel, MD (1) · Paul Rubinstein, MD (1) · Salil Goorha, MD (1) · Stefano Tarantolo, MD (1) · Tamra Slone, MD (1)